Through our culture of collaboration, connectivity and data-based science, MD Anderson experts have set the standard for how immunotherapy is used to treat patients with cancer across the globe. Our faculty are working to bring the benefits of immunotherapy to even more patients by integrating immunobiology across all cancer disciplines. MD Anderson’s unique environment and vast resources allow researchers to accelerate novel discoveries into practice-changing therapies that propel us closer to our goal: a world free of cancer.
At the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, our experts are showcasing pacesetting research and joining colleagues for discussion on the latest science, development and application of immunotherapy.
Below are highlights from our presentations, details about onsite networking opportunities with our experts, and information on our open positions for faculty and trainees.
Featured News
Meet the Experts
Visit MD Anderson at our booth to network with us, ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts. Check back for the updated Meet the Experts schedule soon.
Our research by the numbers
$1.2B
invested in research
1,568
clinical trials
90
patents awarded
From Sept. 1, 2022 to Aug. 31, 2023
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.
Why Houston?
As America's fourth-largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.